The once-daily pill combines Opko’s long-acting GLP-1/glucagon dual agonist peptide, dubbed OPK-88006, with Entera’s N-Tab ...

As obesity drug developers compete for the highest weight-loss efficacy, experts contend that overall health ...

The new $5.3 billion deal with the Swiss pharma giant gives Zealand a significant partner to advance its amylin analog obesity shot and create a new combination product.

IT’S hard to imagine a time when the word ‘Ozempic’ wasn’t part of our vocabulary.  For years, celebs have embraced the ...

A rise in the use of non-FDA-approved diabetes and obesity medications has spurred health care professionals and medical ...

"[Doctors should] be informed that hair loss may be a potential side effect." "With this information, the risk-benefit trad ...

A WOMAN has left TikTok users divided after claiming to have lost seven stone after taking weight loss drug Mounjaro for 11 ...

Enrollment complete in Phase 2 Avail™ trial of canvuparatide in hypoparathyroidism; topline results on track for Q3 2025MBX 1416 Phase 2 trial in ...

In the ever-evolving landscape of healthcare, groundbreaking innovations are not merely celebrated for their scientific ...

The company unveiled plans last week to test its GLP-1/glucagon dual receptor agonist in alcohol use disorder and ...

Weight loss from glucagon-like peptide 1 agonists clearly alleviates knee osteoarthritis pain, but other recently published data give pause regarding possible long-term adverse effects.

Emerging evidence shows glucose-lowering medications may have the potential to improve chronic obstructive pulmonary disease ...